Oncocine is an AI native oncology company building the future of adaptive cancer immunotherapy. We engineer personalised mRNA cancer vaccine assets for pharmaceutical and biotech partners. Our proprietary platform, ONVAC, integrates spatial tumour microenvironment intelligence, multi-omics neoantigen discovery, ML based patient stratification, and adaptive vaccine design into a single end to end pipeline. The output is a portfolio of validated, licensable pre-clinical cancer vaccine assets that pharma partners take through clinical development with the biology already designed to succeed. The founding team brings rare depth across three dimensions. Our award winning CEO is a serial oncology biotech founder with a proven commercial track record and multiple cancer biotech patents. Our CSO brings 25 years of oncology drug discovery and translational medicine leadership. Our CTO is an AI and computational biology pioneer with over two decades of building machine learning infrastructure inside major pharmaceutical organisations. Oncocine delivers validated cancer vaccine assets, accelerated trials, reduced attrition, and manufacturing-ready designs providing an unmatched strategic advantage in precision immunotherapy. Our mission is to develop immunotherapeutics for cancer patients; faster, smarter and personalised.